Clinical Trials Logo

Hypertension clinical trials

View clinical trials related to Hypertension.

Filter by:

NCT ID: NCT05332847 Completed - Clinical trials for POCUS Assessment During Ambulatory PAH Clinic

Point of Care Ultrasonography Assessment During Pulmonary Hypertension Clinic

POCUSPAH
Start date: January 14, 2018
Phase: N/A
Study type: Interventional

Background: Changes occurring in the pulmonary vascularity imparts changes to the right heart in patients with pulmonary arterial hypertension (PAH). Importantly changes in RV function correlates with severity of disease and patient outcome. This affords and opportunity to assess patients longitudinally through point of care ultrasonography. Investigators objective was to measure the percentage and the rate of patients management change, represented by change in treatment or assessment of patients in the PAH clinic, and to compared management change rate between patients with PAH who underwent point of care ultrasonography (POCUS) assessment in addition to the routine evaluation, and a control group to which the investigators did not add a test with POCUS in addition to the routine evaluation in the clinic. Methods: Consecutive patients from the PAH clinic in two medical centers were randomized to the POCUS assessment group and the non-POCUS group. The POCUS group received lung, heart, and vascular ultrasound assessments. All other assessments were the same between both groups. Management changes were documented during each of the patients' visits over a three-month interval.

NCT ID: NCT05331144 Recruiting - Hypertension Clinical Trials

Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study)

IPAT
Start date: October 25, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if intensive lowering of systolic blood pressure (SBP), using FDA approved medications (antihypertensive), reduces Alzheimer's Disease pathology (i.e., excessive brain amyloid and tau protein deposition) in older adults at high risk for memory decline or dementia.

NCT ID: NCT05331014 Completed - Hypertension Clinical Trials

To Evaluate the Efficacy and Safety in Patients With Dyslipidemia and Hypertension

Start date: November 15, 2021
Phase: Phase 3
Study type: Interventional

A Multi-center, Randomized, Double-blind, Parallel, phase III Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0101+C2101 in Patients with Dyslipidemia and Hypertension.

NCT ID: NCT05330949 Recruiting - Clinical trials for Pregnancy Induced Hypertension

Optical Coherence Tomography Angiography Compared to Maternal Doppler in Screening for Hypertension in Pregnancy

Start date: April 1, 2022
Phase:
Study type: Observational

Pregnancy related hypertension is one of the most prevalent obstetric complications. The aim of the study is to evaluate the validity and sensitivity of OCT angiography in prediction of pregnancy induced hypertensive disorders in comparison to maternal doppler in the first and second trimesters of pregnancy

NCT ID: NCT05330221 Recruiting - Hypertension Clinical Trials

Project 2: ACHIEVE- HF

Start date: January 18, 2023
Phase: N/A
Study type: Interventional

This project is part of the ACHIEVE GREATER (Addressing Cardiometabolic Health Inequities by Early PreVEntion in the GREAT LakEs Region) Center (IRB 100221MP2A), the purpose of which is to reduce cardiometabolic health disparities and downstream Black-White lifespan inequality in two cities: Detroit, Michigan, and Cleveland, Ohio. The ACHIEVE GREATER Center will involve three separate but related projects that aim to mitigate health disparities in risk factor control for three chronic conditions, hypertension (HTN, Project 1), heart failure (HF, Project 2) and coronary heart disease (CHD, Project 3), which drive downstream lifespan inequality. All three projects will involve the use of Community Health Workers (CHWs) to deliver an evidence-based practice intervention program called PAL2. All three projects will also utilize the PAL2 Implementation Intervention (PAL2-II), which is a set of structured training and evaluation strategies designed to optimize CHW competence and adherence (i.e., fidelity) to the PAL2 intervention program. The present study is Project 2 of the ACHIEVE GREATER Center.

NCT ID: NCT05329714 Recruiting - Clinical trials for Pulmonary Hypertension

PVRI GoDeep Global Deep Phenotyping Meta-Registry for Pulmonary Hypertension

PVRI GoDeep
Start date: January 30, 2020
Phase:
Study type: Observational

PVRI-GoDeep is a PH Meta-Registry, run under the umbrella of the Pulmonary Vascular Research Institute (PVRI). It merges anonymized PH patient related data from various local registries around the world run under the responsibility of PVRI members. It will be operated under the auspices of the University of Giessen/Giessen PH center. Combining deep phenotyping with worldwide outreach, PVRI-GoDeep aims to offer insights into specific geographical and ethnical profiles of PH, to deepen the epidemiological, clinical and molecular understanding of this disease and to promote strategies for improved individualized treatment of PH patients.

NCT ID: NCT05328921 Recruiting - Hypertension Clinical Trials

Effects of Systemic Drugs on Intraocular Pressure

Start date: April 7, 2022
Phase:
Study type: Observational

To assess intraocular pressure changes among glaucoma patients on systemic antihypertensive and antihistaminic drugs.

NCT ID: NCT05328310 Active, not recruiting - Hypertension Clinical Trials

Effect of Different Antihypertensive Drugs on Central Blood Pressure

Start date: January 6, 2019
Phase: N/A
Study type: Interventional

Trial name) The differential effects of antihypertensive drugs on central blood pressure: comparison between beta-blocker(BB) and angiotensin receptor blocker ARB) Objectives) To evaluate the effect of BB, which has vasodilatory effects, on CBP by comparison between ARB, one of the most widely used class of antihypertensives. Study design) A multicenter, prospective, randomized, controlled, open-label clinical trial for hypertension patients. Patient enrollment) 110 patients will be enrolled at 2 centers in South Korea. Patient follow-up) Patients will go through an initial washout period of two weeks prior to randomization. After pre-medication baseline visit and randomization, clinical follow-up will occur at 4, 8, 12 weeks after initial administration of randomized drug. The follow-up visits are office visits. Primary endpoint) Reduction in CBP at 12 weeks. Secondary endpoints) Clinical events including adverse reactions to the drugs.

NCT ID: NCT05326386 Active, not recruiting - Clinical trials for Hypertension and Hyperlipidemia

Gamification and Medication Adherence (GAME Adherence)

Start date: September 12, 2022
Phase: N/A
Study type: Interventional

A two-arm randomized controlled trial to evaluate whether a gamification intervention plus involvement of a supportive partner (social support) and sending reports to physicians (accountability) increases medication adherence in patients with hypertension and hyperlipidemia. The study will randomize 84 patients with hypertension, hyperlipidemia, and a history of poor medication adherence seen in a single Penn Medicine clinic to an 18-week gamification intervention or to attention control text messages alone.

NCT ID: NCT05326230 Recruiting - Hypertension Clinical Trials

A Clinical Study of the Paradiseā„¢ Renal Denervation System in Patients With Hypertension (RADIANCE-HTN DUO)

Start date: July 1, 2022
Phase: N/A
Study type: Interventional

To compare the antihypertensive effect of renal denervation with the Paradiseā„¢ system with that of a sham procedure in hypertensive patients receiving two antihypertensive drugs at the time of consent, and treated with a duo combination antihypertensive pill.